Author Topic: (Abst.) Association of immunotherapies w/outcomes in RRMS  (Read 87 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Association of immunotherapies w/outcomes in RRMS
« on: January 28, 2016, 10:15:44 am »
Abstract of a meta-analysis--from PubMed, January 28, 2016:

Quote
JAMA. 2016 Jan 26;315(4):409-10. doi: 10.1001/jama.2015.18984.

Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis

Tramacere I1, Del Giovane C2, Filippini G3.

Author information

1Neuroepidemiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
2Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.
3Scientific Direction, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

CLINICAL QUESTION:

What immunotherapies for multiple sclerosis are associated with the greatest benefit and highest risk of discontinuation due to adverse events in patients with relapsing-remitting multiple sclerosis?

BOTTOM LINE:

Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit with regard to relapse prevention. Their association with prevention of disability worsening was unclear. Fingolimod was associated with a high risk of treatment discontinuation due to adverse events.

Comment on
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. [Cochrane Database Syst Rev. 2015]
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.